论文部分内容阅读
目的观察奥扎格雷联合舒血宁治疗急性脑梗死的临床疗效。方法选择114例急性脑梗死患者随机分为治疗组和对照组;对照组采用舒血宁20 ml静脉滴注,每日2次,共14 d。治疗组采用舒血宁20 ml静脉滴注,每日2次,同时应用奥扎格雷80 mg静脉滴注,每日2次,共14 d。对两组患者治疗前及治疗后2周,临床神经功能缺损评分进行分析。结果治疗组临床总有效率为93.1%,明显高于对照组的77.6%,治疗后神经功能缺损程度评分比较有差异统计学意义(P<0.05)。两组无明显不良反应。结论奥扎格雷联合舒血宁治疗急性性脑梗死安全有效。
Objective To observe the clinical efficacy of ozagrel and shuxuening in the treatment of acute cerebral infarction. Methods A total of 114 patients with acute cerebral infarction were randomly divided into treatment group and control group. The control group received Shuxuening 20 ml intravenously twice daily for 14 days. The treatment group with Shuxuening 20 ml intravenous infusion, 2 times a day, while the application of ozagrel 80 mg intravenous infusion twice daily for 14 days. Two groups of patients before treatment and 2 weeks after treatment, clinical neurological deficit score analysis. Results The total clinical effective rate was 93.1% in the treatment group, which was significantly higher than that in the control group (77.6%). There was significant difference in the scores of neurological deficits after treatment (P <0.05). No significant adverse reactions in both groups. Conclusion Ozagrel combined with Shuxuening is safe and effective in the treatment of acute cerebral infarction.